BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23113686)

  • 21. [Invasive yeast infections in neutropenic patients].
    Ruiz Camps I; Jarque I
    Rev Iberoam Micol; 2016; 33(3):170-5. PubMed ID: 27395023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
    Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
    Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.
    Bailly S; Leroy O; Montravers P; Constantin JM; Dupont H; Guillemot D; Lortholary O; Mira JP; Perrigault PF; Gangneux JP; Azoulay E; Timsit JF
    Intensive Care Med; 2015 Nov; 41(11):1931-40. PubMed ID: 26370688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants.
    Mohamed WA; Ismail M
    J Trop Pediatr; 2012 Feb; 58(1):25-30. PubMed ID: 21355042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques.
    Sobel JD
    Pharmacotherapy; 2006 Jun; 26(6 Pt 2):47S-54S. PubMed ID: 16716122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empirical antifungal therapy in treating febrile neutropenic patients.
    Wingard JR
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S38-43. PubMed ID: 15250019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.
    Andes DR; Safdar N; Baddley JW; Playford G; Reboli AC; Rex JH; Sobel JD; Pappas PG; Kullberg BJ;
    Clin Infect Dis; 2012 Apr; 54(8):1110-22. PubMed ID: 22412055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives.
    Neoh CF; Slavin M; Chen SC; Stewart K; Kong DC
    Int J Antimicrob Agents; 2014 Mar; 43(3):207-14. PubMed ID: 24670423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voriconazole versus amphotericin B in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Johansen HK
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EPICO 2.0 PROJECT. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.
    Zaragoza R; Ferrer R; Maseda E; Llinares P; Rodríguez A;
    Rev Esp Quimioter; 2014 Sep; 27(3):196-212. PubMed ID: 25229375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
    Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
    BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis.
    Goldberg E; Gafter-Gvili A; Robenshtok E; Leibovici L; Paul M
    Eur J Cancer; 2008 Oct; 44(15):2192-203. PubMed ID: 18706808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children.
    Caselli D; Cesaro S; Ziino O; Ragusa P; Pontillo A; Pegoraro A; Santoro N; Zanazzo G; Poggi V; Giacchino M; Livadiotti S; Melchionda F; Chiodi M; Aricò M
    Br J Haematol; 2012 Jul; 158(2):249-255. PubMed ID: 22571507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
    Playford EG; Webster AC; Sorrell TC; Craig JC
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004920. PubMed ID: 16437504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Candida tropicalis in human disease.
    Chai LY; Denning DW; Warn P
    Crit Rev Microbiol; 2010 Nov; 36(4):282-98. PubMed ID: 20883082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.
    Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM
    J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
    Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
    Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
    De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
    Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.